Skip to main content

Table 1 Patient characteristics before BPA

From: Bilateral versus unilateral balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension

  CTEPH (N = 92)
Age (years) 59 ± 12
Female (%) 63 (68%)
Number of BPA sessions/patient 2 (1, 3)
Total BPA sessions 210
Interval between BPA (days) 80 (48, 131)
Hemodynamics
 Heart rate 81 ± 13
 Mean RAP (mmHg) 7.4 ± 5.0
 Systolic PAP (mmHg) 75.5 ± 25.6
 Diastolic PAP (mmHg) 24.8 ± 9.0
 Mean PAP (mmHg) 43.0 ± 13.6
 PVR (Wood Unit) 10.3 ± 6.7
 Cardiac output (L/min) 4.1 ± 1.8
 Cardiac index (L/min/m2) 2.6 ± 1.1
 PASO2 (%) 62.5 ± 10.2
 MVSO2 (%) 93.9 ± 4.4
 NT-proBNP (pg/ml) 541.1 (120.0, 1823.8)
Exercise capacity
 WHO functional class (I/II/III/IV, %) 7/45/36/4 (7.6/48.9/39.1/4.3)
PAH targeted therapy (%) 50 (54.3%)
Riociguat 28 (30.4)
Macitentan 11 (12.0)
Treprostinil 10 (10.9)
Tadalafil 8 (8.7)
Sildenafil 7 (7.6)
Ambrisentan 5 (5.4)
Bosentan 4 (4.3)
Anticoagulation (%) 92 (100%)
Warfarin 19 (20.7)
Rivaroxaban 64 (69.6)
Dabigatran 9 (9.8)
  1. Continuous variables are expressed as mean ± standard deviation or median and interquartile range according to variable distribution. CTEPH chronic thromboembolic pulmonary hypertension, BPA balloon pulmonary angioplasty, RAP right atrium pressure, PAP pulmonary artery pressure, PVR pulmonary vascular resistance, PASO2 pulmonary arterial oxygen saturation, MVSO2 mixed venous oxygen saturation, NT-proBNP N-terminal pro-B-type natriuretic peptide, WHO World Health Organization